ScreenerHero

VSTM Verastem, Inc.

NAS · US · Healthcare · Biotechnology · verastem.com
8.265USD+6.65%Mkt Cap: 748.51M $P/E: —

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, which is an orally…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap748.51M USD
Enterprise Value649.84M USD
Revenue (TTM)87.53M USD
Gross Profit25.62M USD
Net Income (TTM)-209.47M USD
Revenue/Share0.98 USD
Last Price8.265 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees102
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-10.33
PEG—
EV/EBITDA-4.10
EV/Revenue7.42
P/S8.02
P/B14.04
EPS (TTM)-2.45
EPS (Forward)-0.75
52W Range
3.43065% of range10.82
52W High10.82 USD
52W Low3.430 USD
Profitability
Gross Margin82.86%
Oper. Margin-81.62%
EBITDA Margin-181.26%
Profit Margin-677.59%
ROE-366.23%
ROA-85.00%
Growth
Revenue Growth1775.40%
Earnings Growth—
Cash Flow & Leverage
Operating CF-137.51M USD
CapEx (TTM)9.62M USD
FCF Margin-118.17%
FCF Yield-13.82%
Net Debt-52.02M USD
Net Debt/EBITDA0.33
Balance Sheet
Debt/Equity1.52
Current Ratio2.25
Quick Ratio2.12
Book Value/Sh0.55 USD
Cash/Share1.51 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split1:12
Split DateJun 1, 2023
Analyst Consensus
Rating1.1 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)14.67 USD
Upside (mean)+77.5%
Target Range11.00 USD – 18.00 USD
11.00+77.5% to mean18.00
# Analysts9
Ownership
Shares Out.90.56M
Float70.50M
Insiders1.09%
Institutions110.94%
Short Interest
Short Ratio8.1d
Short % Float20.02%
Short % Out.19.91%
Shares Short18.03M
Short (prev mo.)18.91M
Technical
SMA 507.208 (+14.7%)
SMA 2006.035 (+36.9%)
Beta0.39
S&P 52W Chg16.45%
Avg Vol (30d)2.32M
Avg Vol (10d)2.15M
Technical Indicators
RSI (14)60.2
MACD0.2618
MACD Signal0.3028
MACD Hist.-0.0410
BB Upper8.449 USD
BB Middle7.845 USD
BB Lower7.240 USD
BB Width15.41%
ATR (14)0.5040 USD
Vol Ratio (20d)1.65x